In last trading session, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) saw 1.55 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $12.69 trading at $0.49 or 3.97% at ring of the bell on the day assigns it a market valuation of $1.74B. That closing price of ARWR’s stock is at a discount of -139.64% from its 52-week high price of $30.41 and is indicating a premium of 4.33% from its 52-week low price of $12.14. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.89 million shares which gives us an average trading volume of 1.92 million if we extend that period to 3-months.
For Arrowhead Pharmaceuticals Inc (ARWR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.67. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) trade information
Upright in the green during last session for gaining 3.97%, in the last five days ARWR remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $12.69 price level, adding 9.36% to its value on the day. Arrowhead Pharmaceuticals Inc’s shares saw a change of -32.50% in year-to-date performance and have moved -8.90% in past 5-day. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) showed a performance of -25.83% in past 30-days. Number of shares sold short was 10.44 million shares which calculate 7.18 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 26.98 to the stock, which implies a rise of 52.97% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 29.97. It follows that stock’s current price would drop -89.13% in reaching the projected high whereas dropping to the targeted low would mean a loss of -89.13% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 47.20% while estimates for its earnings growth in next 5 years are of 11.30%.
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)’s Major holders
Insiders are in possession of 13.19% of company’s total shares while institution are holding 74.66 percent of that, with stock having share float percentage of 86.01%. Investors also watch the number of corporate investors in a company very closely, which is 74.66% institutions for Arrowhead Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ARWR for having 15.68 million shares of worth $407.61 million. And as of 2024-06-30, it was holding 12.6275 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 12.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.9072 of outstanding shares, having a total worth of $317.44 million.
